Published in Phys Biol on November 29, 2012
Evolutionary game theory for physical and biological scientists. II. Population dynamics equations can be associated with interpretations. Interface Focus (2014) 0.82
Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A (2017) 0.75
What's Luck Got to Do with It: Single Cells, Multiple Fates, and Biological Nondeterminism. Mol Cell (2016) 0.75
Stochastic gene expression in a single cell. Science (2002) 34.54
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Bacterial persistence as a phenotypic switch. Science (2004) 15.80
Regulation of noise in the expression of a single gene. Nat Genet (2002) 14.93
Nature, nurture, or chance: stochastic gene expression and its consequences. Cell (2008) 12.13
Intrinsic noise in gene regulatory networks. Proc Natl Acad Sci U S A (2001) 12.06
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Noise in gene expression: origins, consequences, and control. Science (2005) 9.64
Direct cell reprogramming is a stochastic process amenable to acceleration. Nature (2009) 8.71
Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res (1959) 8.59
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med (2003) 7.64
Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature (2008) 7.60
Stochasticity in transcriptional regulation: origins, consequences, and mathematical representations. Biophys J (2001) 7.52
Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell (2011) 7.30
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 7.24
It's a noisy business! Genetic regulation at the nanomolar scale. Trends Genet (1999) 7.09
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Variability and memory of protein levels in human cells. Nature (2006) 6.15
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
Non-genetic individuality: chance in the single cell. Nature (1976) 5.52
Capturing pluripotency. Cell (2008) 5.08
Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol (2009) 4.60
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Cellular decision making and biological noise: from microbes to mammals. Cell (2011) 4.44
Molecular basis for trypanosome antigenic variation. Cell (1982) 3.80
IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature (2007) 3.74
Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A (2011) 3.42
Living with noisy genes: how cells function reliably with inherent variability in gene expression. Annu Rev Biophys Biomol Struct (2007) 3.36
Architecture-dependent noise discriminates functionally analogous differentiation circuits. Cell (2009) 3.05
Systems biology of stem cell fate and cellular reprogramming. Nat Rev Mol Cell Biol (2009) 2.93
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol (2007) 2.70
Non-genetic heterogeneity--a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet (2009) 2.69
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev (2010) 2.51
Non-genetic heterogeneity of cells in development: more than just noise. Development (2009) 2.48
Cellular and genetic aspects of antigenic variation in trypanosomes. Annu Rev Immunol (1990) 2.44
Non-genetic heterogeneity from stochastic partitioning at cell division. Nat Genet (2010) 2.32
The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med (2005) 2.24
Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol (2009) 2.05
In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med (2006) 1.88
The logic of EGFR/ErbB signaling: theoretical properties and analysis of high-throughput data. PLoS Comput Biol (2009) 1.88
Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol (2011) 1.86
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct (2010) 1.69
The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol (2012) 1.65
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. Mol Biol Cell (2011) 1.54
Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep (1970) 1.54
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol (2009) 1.43
CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta (2010) 1.43
HER2 as a prognostic factor in breast cancer. Oncology (2001) 1.43
Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines. Mol Cell Biol (1981) 1.42
Her2-positive breast cancer: herceptin and beyond. Eur J Cancer (2008) 1.39
Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett (2001) 1.36
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Rapid spontaneous dihydrofolate reductase gene amplification shown by fluorescence-activated cell sorting. Proc Natl Acad Sci U S A (1983) 1.30
The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol (2005) 1.24
Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors. Phys Biol (2011) 1.22
Microbiology. Noninherited resistance to antibiotics. Science (2004) 1.17
Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. Acad Radiol (2010) 1.09
Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. PLoS One (2011) 1.08
High-time chemotherapy or high time for low dose. J Clin Oncol (2000) 1.06
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med (2007) 1.05
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res (2001) 1.00
The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat (1996) 0.99
Gene expression noise facilitates adaptation and drug resistance independently of mutation. Phys Rev Lett (2011) 0.98
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer (2008) 0.98
Rapid emergence of methotrexate resistance in cultured mouse cells. Cancer Res (1984) 0.97
Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol (2000) 0.96
Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics (1990) 0.96
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology (2002) 0.95
A mathematical model of breast and ovarian cancer treated with paclitaxel. Math Biosci (1997) 0.94
Dynamic heterogeneity and metastasis. J Cell Physiol Suppl (1984) 0.93
DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res (Phila) (2009) 0.93
The emerging low-dose therapy for advanced cancers. Dose Response (2009) 0.91
Random and nonrandom processes in metastasis, and metastatic inefficiency. Invasion Metastasis (1983) 0.90
Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol (2006) 0.84
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J Pediatr Hematol Oncol (2011) 0.83
Nuclear origins of cell-to-cell variability. Cold Spring Harb Symp Quant Biol (2011) 0.82
Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med (2004) 0.77
Stability analysis of normal and neoplastic growth. Bull Math Biol (1977) 0.76
Characterization of phenotypic switching in Cryptococcus neoformans biofilms. Mycopathologia (2008) 0.76
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov (2012) 2.51
p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol (2006) 2.39
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell (2004) 1.66
DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet (2013) 1.64
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Tumor microenvironment and progression. J Surg Oncol (2011) 1.54
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Res (2013) 1.33
Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A (2013) 1.31
Simulating properties of in vitro epithelial cell morphogenesis. PLoS Comput Biol (2006) 1.24
p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res (2005) 1.15
p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res (2006) 1.13
Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia (2013) 1.11
Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res (2007) 1.05
Primary cilia regulate branching morphogenesis during mammary gland development. Curr Biol (2010) 1.03
Graphical methods for quantifying macromolecules through bright field imaging. Bioinformatics (2008) 1.02
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res (2003) 1.00
Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99
Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes. Breast Cancer Res (2012) 0.97
Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res (2009) 0.97
Conceptualizing a tool to optimize therapy based on dynamic heterogeneity. Phys Biol (2012) 0.93
Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev Res (Phila) (2010) 0.91
Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response. Mol Cell (2013) 0.87
Unprecedented opportunities and promise for cancer prevention research. Cancer Prev Res (Phila) (2010) 0.86
Reflections on miR-ing effects in metastasis. Cancer Cell (2009) 0.78
Luminal cells GATA have it. Nat Cell Biol (2007) 0.78
Hello out there...is anybody listening? Cancer Discov (2012) 0.75
Towards aspirin-inspired self-immolating molecules which target the cyclooxygenases. Org Biomol Chem (2015) 0.75